Sheba медициналық орталығы
| Израиль | Түркия | Австрия | |
| Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау | бастап $135,000 | бастап $80,000 | бастап $180,000 |
| Туыстық донордан алынған сүйек кемігін аллогендік трансплантациялау | бастап $142,000 | бастап $65,000 | бастап $150,000 |
| Сүт безі рагында химиотерапия | бастап $22,500 | бастап $1,200 | бастап $15,000 |
| Сүйек кемігін трансплантациялау | бастап $75,000 | бастап $36,000 | бастап $140,000 |
| Аутологиялық сүйек кемігін трансплантациялау | бастап $58,000 | бастап $31,500 | бастап $50,000 |
Доктор Рам Рон — Тель-Авив Сураски медициналық орталығының гематоонкология және сүйек кемігін трансплантациялау саласындағы қауымдастырылған профессоры және жетекші маманы.
Доктор Ронит Эль-Хасид — жетекші педиатр. Ол Дана Двек балалар ауруханасында жілік майы мен кіндік қанын ауыстырып салу бойынша 300-ден астам операция жасаған.
Сураски медициналық орталығында (Ихилов) фолликулярлық лимфоманы емдеудің негізгі әдісі болып табылатын бірнеше жүз діңгекті жасушаларды трансплантациялауды жүзеге асырды.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Leading Israeli hospitals specializing in follicular lymphoma include Sheba Medical Center, Sourasky Medical Center, and Hadassah Medical Center. These centers are JCI-accredited and utilize advanced PET/CT imaging and CAR T-cell therapy. Highly experienced hematologists develop personalized protocols for both adult and pediatric patients.
Bookimed Expert Insight: Israeli oncology centers prioritize mid-course therapy adjustments based on interim PET/CT scans. Data shows that clinics like Sheba and Sourasky often integrate Phase I/II CAR-T trials directly into follicular lymphoma care. This offers patients access to novel cellular therapies when standard watch-and-wait protocols end.
Patient Consensus: Patients note that bringing complete medical records and prior scans speeds up the second-opinion process. They often recommend requesting genomic mutation screening early to help doctors choose the most effective targeted therapy.
Israel offers advanced follicular lymphoma treatments including CAR T-cell therapy, allogeneic bone marrow transplantation, and precision immunotherapy. Academic centers like Sheba Medical Center and Sourasky Medical Center utilize molecular diagnostics to personalize drug protocols. These facilities report survival rates reaching 100% for specific patient cohorts.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky Medical Center manage massive patient volumes, often exceeding 400,000 annually. This high frequency allows surgeons like Dr. Arnon Nagler and Dr. Ronit El Hasid to maintain mastery in complex procedures. Their expertise is a primary reason why survival rates for certain lymphoma protocols approach 100%.
Patient Consensus: Patients often emphasize the value of `biopsy revision` in Israel, as local pathology experts frequently refine initial diagnoses. Many travelers note the comfort of 30-day hospital stays included in comprehensive bone marrow transplant packages.
CAR-T therapy in Israel is readily available to international patients through specialized programs. Major centers maintain high safety standards with manageable toxicity levels. The treatment process typically lasts 4 to 6 weeks. Specialists prioritize long-term remission for relapsed or refractory B-cell malignancies and lymphomas.
Bookimed Expert Insight: While Israel is a global leader in CAR-T, the real advantage lies in the integration of pediatric expertise. Dr. Amos Toren at Sheba and Dr. Ronit El Hasid at Sourasky have combined experience in over 3,000 advanced cellular procedures. This high volume across JCI-accredited facilities often leads to more refined protocols for managing side effects compared to lower-volume regional centers.
Patient Consensus: Patients note that while the medical care is exceptional, budgeting carefully for post-infusion monitoring is vital. They often highlight that English-speaking staff and the seamless approval process make the logistical transition much easier than expected.
Initial consultations in Israel focus on integrating medical history into the national digital system. You should clarify specialist referral paths and medication inclusion in the Health Basket. Ask about precision diagnostics like PET/CT scans and molecular markers. Verify if your current records are accessible through local health fund apps.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky prioritize high-volume expertise. Dr. Abraham Avigdor and Dr. Avichai Shimoni each possess over 30+ years of experience. This deep specialization enables them to manage complex stem cell transplants for high-risk lymphoma cases effectively. Patients often choose these centers because their physicians lead national committees deciding which medications enter the subsidized Health Basket.
Patient Consensus: Patients emphasize asking about fertility preservation before starting chemotherapy. They also recommend requesting a second opinion on biopsy results to ensure accurate subtyping before treatment begins.
International patients typically stay in Israel for 1 to 3 weeks. Diagnostics for follicular lymphoma generally take 3 to 4 days. Initial therapy cycles vary by complexity. Standard chemotherapy requires 7 to 14 days. Intensive treatments like bone marrow transplants include 30-day hospitalizations.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba specialize in complex hematology. While diagnostics are rapid, patients often choose All-inclusive packages to manage high costs. Packages from Sheba Medical Center cover both 30-day hospital stays and airport-clinic-hospital transfers. Choosing clinics with structured packages helps avoid the $150,000+ logistics of separate billing.
Patient Consensus: Patients advise planning for at least 2 to 4 weeks to manage potential scheduling delays. many recommend booking local apartments to stay comfortable while waiting for post-infusion observation periods.
Patients treating follicular lymphoma in Israel can travel between sessions with medical approval. Work is legally restricted to specific visa holders. Major centers like Sheba Medical Center and Sourasky Medical Center offer excellent connectivity to Tel Aviv and Jerusalem for sightseeing during breaks.
Bookimed Expert Insight: Israeli medical centers are highly concentrated in the center of the country. Sourasky Medical Center is in the heart of Tel Aviv. Sheba Medical Center is in Ramat Gan. This proximity allows patients to stay in urban areas without missing complex treatments like CAR-T immunotherapy. You can enjoy the city while remaining within 20 minutes of world-class specialists.
Patient Consensus: Patients mention that staying near the seaside improves their mood during treatment. They recommend using the local train system as it is reliable and wheelchair accessible.